ORGN vs GEVO vs LNZA vs VVOS vs LOOP

For growth investors, Loop Industries, Inc.

(LOOP) is the stronger pick with 70. 2% revenue growth year-over-year, versus -20. 8% for LanzaTech Global, Inc. (LNZA). Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gevo, Inc.

(GEVO) delivered a total return of -65. 2%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: LOOP returned -90. 8% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 74β versus Origin Materials, Inc. 's 1. 68β — meaning ORGN is approximately 128% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 3% versus 8% for Loop Industries, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Loop Industries, Inc.

(LOOP) is pulling ahead at 70. 2% versus -20. 8% for LanzaTech Global, Inc. (LNZA). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to -441. 2% for Origin Materials, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gevo, Inc.

(GEVO) is the more profitable company, earning -21. 1% net margin versus -277. 7% for LanzaTech Global, Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — LOOP leads at 95. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74)). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VVOS: -99. 7%, ORGN: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ORGN (Basic Materials) and GEVO (Basic Materials) and LNZA (Industrials) and VVOS (Healthcare) and LOOP (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ORGN is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; LNZA is a small-cap quality compounder stock; VVOS is a small-cap quality compounder stock; LOOP is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.